Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GALILEO-1 phase 1/2 study of FLT201 in adults with Gaucher disease type 1
MOH_2021-10-18_010335Phase 2Not yet recruiting
- Sponsor
- Freeline Therapeutics
- Start
- May 2021
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of avigbagene parvec in Gaucher disease type 1 (GD1) (2 cohorts), sponsored by Freeline Therapeutics. Primary endpoint: Safety and tolerability of FLT201. Planned start May 2021; status: not yet recruiting.
02
Drugs
avigbagene parvec
03
Conditions
Gaucher disease type 1 (GD1)
Beyond the preview
Go deeper on MOH_2021-10-18_010335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-10-18_010335.